On Friday, my favorite little boom or bust biotech, Bioasis, reported their results. There is very little to learn from looking at the numbers; this is a tiny, pre-revenue company. However, in the MD&A section of the filing was...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas...
Tailwinds' Take: Nice to see this patent as it shows they continue to make progress behind the scenes, despite their noticeable lack of marketing around the company and its shares.  Guilford, CT. Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or...
I’ve held off on my August recap much like a war veteran will refrain from telling tales from the trenches. Not that my experiences are nearly as terrible as a real war, but in the figurative sense, August left...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system...
This week Bioasis heard back from the FDA on written questions they had submitted. These questions concern their lead investigational candidate xB3-001 and its development path. The Company’s goal, of course, is to bring this therapeutic into clinical development...
Tailwinds' Take: Positive in that the timeline for development appears to be unchanged post the meeting, so that implies there were no significant issues from the FDA's side. How they fund this going forward remains a mystery to me....
Tailwinds' Take: this is a nice announcement, securing more IP around this platform technology. We remain intrigued by the Company, especially at this valuation, but would like to see a clearer path to financing before stepping up in a...
I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a swoon. This time, thanks to the ratcheting up of trade tension, we looked ready for...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.